Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.47 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9728009 | 0.83 | NMUR2 (0.53) | NMUR2NMUR1NTSR2NTSR1EPHA2 | |
| SCHEMBL9852750 | 0.78 | NPY4R (0.58) | NMUR2NMUR1EPHA2OPRM1OPRD1 | |
| SCHEMBL10588690 | 0.78 | NPY4R (0.61) | NMUR2NMUR1 | |
| SCHEMBL29520140 | 0.77 | OPRM1 (0.57) | NMUR2NMUR1NTSR2NTSR1SORT1 | |
| SCHEMBL5499951 | 0.77 | NPY4R (0.58) | NMUR2NMUR1NTSR2NTSR1SORT1 | |
| SCHEMBL9631336 | 0.77 | NPY4R (0.51) | NMUR2NMUR1 | |
| SCHEMBL30943512 | 0.76 | NTSR2 (0.56) | NMUR2NMUR1NTSR2NTSR1SORT1 | |
| SCHEMBL9631995 | 0.76 | NPY4R (0.52) | NMUR2NMUR1 | |
| SCHEMBL29619531 | 0.75 | NPY4R (0.58) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL13402619 | 0.75 | OPRM1 (0.58) | NMUR2NMUR1NTSR2NTSR1EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | disclosed |